Search Results
Feb 10, 2026, 09:00 ET AsymBio establece plataformas tecnológicas integradas para el desarrollo biofarmacéutico
cisteínas intercatenarias. La Caja de Herramientas de Conjugación fue preseleccionada en la categoría de "Mejor Tecnología de Plataforma ADC" en los Premios Mundiales ADC 2025.Plataforma de desarrollo de productos farmacéuticos IMPACT: ofrece desarrollo de productos farmacéuticos
More news about: AsymBio
Feb 10, 2026, 09:00 ET AsymBio crée des plates-formes technologiques intégrées couvrant l'ensemble du cycle de développement biopharmaceutique
pontage de cystéine entre les chaînes. La Conjugation Toolbox a été présélectionnée dans la catégorie "Meilleure technologie de plateforme ADC" lors des 2025 World ADC Awards.5. Plate-forme de développement de produits pharmaceutiques IMPACT - Elle permet le développement de produits
More news about: AsymBio
Feb 10, 2026, 09:00 ET AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle
cysteine approaches, glyco-remodeling, and interchain cysteine re-bridging. The Conjugation Toolbox was shortlisted in the "Best ADC Platform Technology" category at the 2025 World ADC Awards.IMPACT Drug Product Development Platform — Delivers indication-, molecule-, and phase-accountable drug
More news about: AsymBio
Feb 10, 2026, 09:00 ET AsymBio etabliert integrierte Technologieplattformen, die den gesamten Lebenszyklus der biopharmazeutischen Entwicklung abdecken
technischen Cystein-Ansätzen, Glyco-Remodeling und Interchain-Cystein-Reverbridging. Die Conjugation Toolbox wurde bei den World ADC Awards 2025 in der Kategorie "Best ADC Platform Technology" in die engere Wahl gezogen.IMPACT Drug-Produktentwicklungsplattform- Bietet
More news about: AsymBio
Feb 10, 2026, 09:00 ET AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle
cysteine approaches, glyco-remodeling, and interchain cysteine re-bridging. The Conjugation Toolbox was shortlisted in the "Best ADC Platform Technology" category at the 2025 World ADC Awards.IMPACT Drug Product Development Platform — Delivers indication-, molecule-, and phase-accountable
More news about: AsymBio
Feb 10, 2026, 08:07 ET On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully
CaoChairman, Minghui PharmaNext-Generation ADC Molecule DesignThe development of innovative drugs is inherently long and high-risk, relying on scientific innovation, technological support, outstanding teams, and perseverance. ADC represents a major breakthrough in cancer therapy, now
More news about: Sanyou Bio
Feb 09, 2026, 08:00 ET BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
for BioDlink's technical expertise and service excellence.Advancing Innovation in ADC DevelopmentThe successful progression of KH815 underscores the growing potential of dual-payload ADC technologies and highlights the value of close collaboration across industry and research. BioDlink
More news about: BioDlink Biopharm Co., Ltd.
Feb 06, 2026, 04:00 ET Kelun-Biotech Announces Fourth Indication for Sacituzumab Tirumotecan (sac-TMT) Approved by NMPA in HR+/HER2- Breast Cancer
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-biotech
Feb 05, 2026, 21:26 ET Akeso Receives Fifth Breakthrough Therapy Designation from NMPA for Ivonescimab in First-Line Treatment of Advanced Biliary Tract Cancer
Founded in 2012, the company has established a robust R&D innovation ecosystem centered on its proprietary Tetrabody bispecific antibody platform, ADC (Antibody-Drug Conjugate) technologies, siRNA/mRNA modalities, and cell therapies. Supported by a global-standard GMP manufacturing infrastructure and
More news about: Akeso, Inc.
Feb 05, 2026, 10:07 ET DigiKey Adds More Than 108,000 New Stocking Parts and 364 Suppliers in 2025
Silanna Semiconductor is a developer and manufacturer of analog technologies, including ADC data converters and Laser Driver ICs.The company's inventory expansion also provides customers with access to the most innovative new product
More news about: DigiKey
Feb 05, 2026, 06:44 ET Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
more than 40 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43 and the novel epitope anti-HER2 mAb HLX22—are advancing through global pivotal clinical development. Supported by a biologics manufacturing network
More news about: Henlius
Feb 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Company.About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Feb 02, 2026, 10:00 ET ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
highlighted China's unique advantages in clinical speed, platform iteration, and portfolio strategy, predicting globally competitive innovations in ADC, TCE, and novel cell/gene therapies in the coming years.Cardio-Renal-Metabolic Session: Experts emphasized de-risking clinical trials and recognized
More news about: ACROBiosystems
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
2026, with cash and cash equivalents of approximately $261 million providing runway at least to 2028. ADC Therapeutics has also completed IND-enabling activities for its PSMA-targeting ADC program.Greenwich LifeSciences (NASDAQ: GLSI) announced the FDA has
More news about: Equity Insider
Jan 28, 2026, 23:51 ET Ivonescimab Included in FirstWord Pharma's "The Drugs That Will Shape 2026"
Alongside ivonescimab, the list highlights transformative therapies such as Eli Lilly's Alzheimer's treatment Kisunla, AstraZeneca/Daiichi Sankyo's ADC Datroway, Novartis' antisense oligonucleotide Pelacarsen, and Moderna/Merck's personalized mRNA cancer vaccine intesmeran autogene. Other featured assets
More news about: Akeso, Inc.
Jan 28, 2026, 04:01 ET ABU DHABI CUSTOMS PARTNERS WITH CRIMSONLOGIC TO DEVELOP AN AI-ENABLED INTEGRATED CUSTOMS OPERATIONS SYSTEM
ABU DHABI, UAE, Jan. 28, 2026 /PRNewswire/ -- Abu Dhabi Customs (ADC) today announced a strategic partnership with CrimsonLogic, a wholly-owned subsidiary of PSA International, to develop the Integrated Customs Operations System (ICOS), an Artificial Intelligence
More news about: CrimsonLogic
Jan 27, 2026, 04:00 ET BIOSeedin Winter Innovation Partnering Summit : pleins feux sur J.P.Morgan
auto-immunes. Les 18 biotechs chinoises ont présenté des actifs de haute qualité dans des domaines de pointe tels que les anticorps bispécifiques, les ADC et les colles moléculaires, s'alignant sur les points chauds de l'industrie et démontrant des réalisations fructueuses en matière de R&D dans des
More news about: bioSeedin
Jan 27, 2026, 04:00 ET Cumbre de colaboración para la innovación de invierno de BIOSeedin: J.P.Morgan en el punto de mira
enfermedades autoinmunes. Las 18 empresas biotecnológicas chinas presentaron activos de alta calidad en campos de vanguardia como anticuerpos biespecíficos, ADC y adhesivos moleculares, en sintonía con los puntos fuertes de la industria y demostrando logros fructíferos en I+D en sectores nicho.Esta cumbre
More news about: bioSeedin
Jan 26, 2026, 17:31 ET RET Fusion Targeted Therapies Market Set for Robust Growth by 2034 Amid Precision Oncology Shift | DelveInsight
drivers, market barriers, and key ADC companies, including AbbVie, Genmab, Daiichi Sankyo, AstraZeneca, Astellas, Roche, Pfizer (Seagen), Takeda, Ambrx, Daiichi Sankyo, Merck, Eisai, Bristol-Myers Squibb, Sanofi, NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics,
More news about: DelveInsight Business Research, LLP
Jan 26, 2026, 09:00 ET Hesai Ranks No.1 in the World for Lidar Patents by KnowMade
Hesai is the only lidar company in the world to develop all seven core components in-house, including its laser transmitter, receiver, driver, TIA, ADC, digital signal processor, and controller. Sixteen of Hesai's in-house developed ASICs have received AEC-Q automotive qualification, with total deliveries
More news about: Hesai Technology
Jan 22, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are advised to contact Danielle Peyton at
More news about: Pomerantz LLP
Jan 22, 2026, 09:00 ET Mabwell Announces First-Patient Dosed in Clinical Trial of Novel CDH17-Targeting ADC 7MW4911 in the U.S.
dosed in a clinical trial in the U.S. of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for the treatment of advanced colorectal cancer and other advanced gastrointestinal tumors. The Phase I/II study (NCT07216560)
More news about: Mabwell
Jan 22, 2026, 06:41 ET Tanmiah Showcases Innovation Excellence at Gulfood 2026 with Three Innovation Award Shortlists
innovations, and tailored solutions, all designed to support their business needs.Marcos Delorenzo, CEO of Agricultural Development Company (ADC), Tanmiah's Poultry Division, added: "Innovation is embedded across our poultry operations, from product development through to logistics
More news about: Tanmiah Food Company
Jan 22, 2026, 06:18 ET Tanmiah Showcases Innovation Excellence at Gulfood 2026 with Three Innovation Award Shortlists
innovations, and tailored solutions, all designed to support their business needs.Marcos Delorenzo, CEO of Agricultural Development Company (ADC), Tanmiah's Poultry Division, added: "Innovation is embedded across our poultry operations, from product development through to logistics
More news about: Tanmiah Food Company
Jan 20, 2026, 07:45 ET Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
received prior bevacizumab and mirvetuximab soravtansine, if eligible. Sofetabart mipitecan is a novel folate receptor alpha (FRα) antibody-drug conjugate (ADC) that uses proprietary linker technology and an exatecan payload. Breakthrough Therapy designation aims to expedite the development and review
More news about: Eli Lilly and Company